Lung cancer in combined pulmonary fibrosis and emphysema: A series of 47 western patients

Journal of Thoracic Oncology

Volumn 9, Issue 8, 2014, Pages 1162-1170

  Girard, Nicolas ^a   Marchand Adam, Sylvain ^b   Naccache, Jean Marc ^c   Borie, Raphael ^d   Urban, Thierry ^e   Jouneau, Stéphane ^f   Marchand, Eric ^g   Ravel, Anne Claire ^h   Kiakouama, Lize ^a   Etienne Mastroianni, Bénédicte ^a   Cadranel, Jacques ^c   Cottin, Vincent ^a   Cordier, Jean François ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE RENNES 1   (France)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h Hôpital de Bourgoin Jallieu   (France)

Author keywords

Combined pulmonary fibrosis and emphysema syndrome; Lung cancer; Orphan disease. Tobacco smoking

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON MONOXIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC RESPIRATORY FAILURE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINED PULMONARY FIBROSIS AND EMPHYSEMA SYNDROME; ENDOSCOPIC THERMOCOAGULATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG SARCOMATOID CARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; SMOKING; STEREOTACTIC RADIOTHERAPY; STEREOTACTIC TREATMENT; THERMOCOAGULATION; TRANSFER FACTOR FOR CARBON MONOXIDE; ADJUVANT THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; EMPHYSEMA; FRANCE; LUNG GAS EXCHANGE; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; SURVIVAL RATE; SYNDROME; VITAL CAPACITY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DYSPNEA; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; FRANCE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONECTOMY; PULMONARY FIBROSIS; PULMONARY GAS EXCHANGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL RATE; SYNDROME; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84905833909     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000209     Document Type: Article

References (50)

1. Cottin V, Nunes H, Brillet PY, et al.; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-593.
2. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990;84:365-369.
3. Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest 2009;136:1-2.
4. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-15.
5. Cottin V, Le Pavec J, Prévot G, et al.; GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010;35:105-111.
6. Sakai F, Tominaga J, Kaga A, et al. Imaging diagnosis of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema). Pulm Med 2012;2012:816541.
7. Cordier JF, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J 2013;42:916-923.
8. Portillo K, Morera J. Combined Pulmonary Fibrosis and Emphysema Syndrome: A New Phenotype within the Spectrum of Smoking-Related Interstitial Lung Disease. Pulm Med 2012;2012:867870.
9. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 2011;16:326-331.
10. Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 2010;15:265-271.
11. Cottin V, Nunes H, Mouthon L, et al.; Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011;63:295-304.
12. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart.World Health Organization Classification of Tumours. Lyon: IARC Press; 2004
13. Miller MR, Hankinson J, Brusasco V, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
14. Austin JH, Müller NL, Friedman PJ, et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996;200:327-331.
15. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
17. National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0and v.4.0 (CTCAE). Available at: http://ctep.cancer.gov/ protocolDevelopment/ electronic-applications/ctc.htm. Accessed September 21, 2013.
18. Grivaux M, Locher C, Oster JP, et al. Amélioration de la survie à 1 an chez les patients atteints d'un cancer broncho-pulmonaire (CBP) primitif: études KBP-2000-CPHG (n = 5667) et KBP-2010-CPHG (n = 7051). Rev Mal Respir 2013;30(S1):A17
19. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001;31:139-148.
20. Asamura H, Goya T, Koshiishi Y, et al.; Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
21. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001;17:1216-1219.
22. Kishi K, Homma S, Kurosaki A, Motoi N, Yoshimura K. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr 2006;30:95-99.
23. Sakai S, Ono M, Nishio T, Kawarada Y, Nagashima A, Toyoshima S. Lung cancer associated with diffuse pulmonary fibrosis: CT-pathologic correlation. J Thorac Imaging 2003;18:67-71.
24. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011;155:137-144.
25. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S.
26. Brunelli A, Belardinelli R, Refai M, et al. Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection. Chest 2009;135:1260-1267.
27. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 2003;125:1321-1327.
28. Takeda A, Enomoto T, Sanuki N, et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med 2008;26:504-507.
29. Suzuki H, Sekine Y, Yoshida S, et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 2011;41:914-921.
30. De Jaeger K, Seppenwoolde Y, Boersma LJ, et al. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;55:1331-1340.
31. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S.
32. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 2011;101:250-254.
33. Griffioen GHMJ, Lagerwaard FJ, Haasbeek CJA, et al. Treatment of multiple primary lung cancers (MLPC) with stereotactic ablative radiotherapy (SABR). Lung Cancer 2013; 80:S22
34. Minegishi Y, Takenaka K, Mizutani H, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009;48:665-672.
35. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005;60:570-575.
36. Pillai SG, Ge D, Zhu G, et al.; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5:e1000421.
37. Liu T, Ullenbruch M, Young Choi Y, et al. Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol 2013;49:260-268.
38. Uematsu K, Yoshimura A, Gemma A, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 2001;61:8527-8533.
39. Calabrese F, Lunardi F, Balestro E, et al. Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis. Pathology 2012;44:192-198.
40. Topic A, Ljujic M, Nikolic A, et al. Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung cancer. Pathol Oncol Res 2011;17:75-80.
41. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009;84:52-59.
42. Massion PP, Zou Y, Chen H, et al. Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med 2008;178:1164-1172.
43. Butler MW, Fukui T, Salit J, et al. Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer. Cancer Res 2011;71:2572-2581.
44. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010;35:496-504.
45. Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. J Natl Compr Canc Netw 2012;10:240-265.
46. Jacobson FL, Austin JH, Field JK, et al. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg 2012;144:25-32.
47. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 2013;63:107-117.
48. Field JK, Baldwin D, Brain K, et al.; UKLS Team. CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax 2011;66:736-737.
49. Couraud S, Cortot AB, Greillier L, et al.; French lung cancer screening statement taskforce; groupe d'Oncologie de langue française. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF). Ann Oncol 2013;24:586-597.
50. Sverzellati N, Guerci L, Randi G, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J 2011;38:392-400.